secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001437749-24-004155
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma reports Q2 fiscal 2024 operating income of $2.4M, first positive; ADHD revenue up 49%
--------------------------------------------------------------------------------

- Consolidated net revenue $22.9M, down 13% YoY due to planned wind-down of Consumer Health Segment.
- ADHD Portfolio revenue jumped 49% to $16.6M; Rx Segment gross margin improved to 78% from 72%.
- Operating income $2.4M vs. operating loss of $6.9M a year ago; net loss narrowed to $0.2M from $6.7M.
- Adjusted EBITDA $5.1M (up 599% YoY); cash $19.5M at Dec 31, 2023.
- Company winding down Consumer Health Segment to focus on Rx Segment; expects neutral segment EBITDA for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/0001437749-24-004155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924004155/aytu20240109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-004155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer